Conference Paper: SARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection

File Download
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleSARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection
AuthorsZheng, B
Du, L
Zhao, G
Lin, Y
Sui, H
Chan, CS
He, Y
Jiang, S
Zhou, Y
Yuen, KY
Issue Date2010
PublisherPortland Press Ltd.. The Journal's web site is located at http://www.cellbiolint.org/cbi/default.htm
CitationThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62 [How to Cite?]
AbstractWe have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.
DescriptionTheme: New Advances and Challenges in Multidisciplinary Research
主題: 多學科交叉研究的新進展與挑戰
ISSN1065-6995
2011 Impact Factor: 1.482
2011 SCImago Journal Rankings: 0.166
DC Field
Value
dc.contributor.authorZheng, B
dc.contributor.authorDu, L
dc.contributor.authorZhao, G
dc.contributor.authorLin, Y
dc.contributor.authorSui, H
dc.contributor.authorChan, CS
dc.contributor.authorHe, Y
dc.contributor.authorJiang, S
dc.contributor.authorZhou, Y
dc.contributor.authorYuen, KY
dc.date.accessioned2011-07-27T02:00:05Z
dc.date.available2011-07-27T02:00:05Z
dc.date.issued2010
dc.description.abstractWe have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.
dc.description.naturelink_to_OA_fulltext
dc.descriptionTheme: New Advances and Challenges in Multidisciplinary Research
dc.description主題: 多學科交叉研究的新進展與挑戰
dc.description.otherThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62
dc.identifier.citationThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62 [How to Cite?]
dc.identifier.epageS62
dc.identifier.hkuros188731
dc.identifier.issn1065-6995
2011 Impact Factor: 1.482
2011 SCImago Journal Rankings: 0.166
dc.identifier.issue8
dc.identifier.spageS62
dc.identifier.urihttp://hdl.handle.net/10722/135932
dc.identifier.volume34
dc.languageeng
dc.publisherPortland Press Ltd.. The Journal's web site is located at http://www.cellbiolint.org/cbi/default.htm
dc.publisher.placeUnited Kingdom
dc.relation.ispartofCell Biology International
dc.rightsThe final version of record is available at [Journal URL].
dc.titleSARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection
dc.typeConference_Paper